Efficacy and Safety of Imatinib in Chordoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

55 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-10-31

Study Completion Date

2008-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Preliminary response data, observed by Casali (Cancer, 2004) with imatinib 800 mg/day in patients affected by chordoma, need to be confirmed by a Phase II study, whose primary endpoint will be the formal assessment of clinical and pathological response. Aim of the study will be to explore treatment's activity, but also the potential impact of tumor response, the feasibility and outcome of subsequent surgery and radiotherapy. In addition, patterns of tumour response need to be investigated as well, given the peculiar patterns of response shown with molecular-targeted therapy in solid tumors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors

NCT00427583

Malignant Peripheral Nerve Sheath Tumors

TERMINATED PHASE2/PHASE3

Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell Tumors

NCT00417807

Refractory Desmoplastic Small Round Cell Tumors

COMPLETED PHASE1/PHASE2

Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

NCT00154388

Life Threatening Diseases

COMPLETED PHASE2

Imatinib Mesylate in Treating Patients With Recurrent Meningioma

NCT00045734

Adult Grade I Meningioma Adult Grade II Meningioma Adult Grade III Meningioma +3 more

COMPLETED PHASE2

Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma

NCT04042597

Effect of Drugs Quality of Life Chordoma +1 more

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chordoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

imatinib

Group Type EXPERIMENTAL

imatinib

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

imatinib

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Histological diagnosis of chordoma.
2. Biomolecular or immunohistochemical evidence of Imatinib mesylate target (PDGFRβ activation and/or presence of PDGFB). Biomolecular assessment of PDGFRβ activation should be made whenever possible. To this end, if frozen material is not available, obtaining of, fresh material is encouraged, if it should be obtained with no major distress for the patient, preferably through an incisional biopsy (to allow immunoprecipitation) or, if this is not feasible, a Trucut biopsy (to allow Western Blot assessment). However, if frozen or fresh material cannot be obtained, paraffined material is also acceptable.

The biomolecular assessment will be centralized to the reference centers (to be defined).
3. Measurable or evaluable disease
4. Surgical resection of local disease unfeasible radically, or unaccepted by the patient, or amenable to become less demolitive, or easier, or likely more feasible, after cytoreduction, and/or metastatic disease. Debulking surgery before enrolment is allowed. In this case, enrolment should occur at least one month after surgery
5. Performance status 0, 1, 2 or 3 (ECOG) (see § 8.1).
6. Adequate end organ function, defined as the following: total bilirubin \<1.5 x ULN, SGOT and SGPT \<2.5 x UNL (or \<5 x ULN if hepatic metastases are present), creatinine \<1.5 x ULN.
7. Adequate bone marrow function, defined as the following: ANC \>1.5 x 10\^9/L, platelets \>100 x 10\^9/L, Hb \>9 g/dL. Blood transfusions are allowed to reach the baseline requested Hb level.
8. Female patients of child-bearing potential must have negative pregnancy test within 7 days before initiation of study drug dosing. Post menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Male and female patients of reproductive potential must agree to employ an effective method of birth control throughout the study and for up to 3 months following discontinuation of study drug.
9. Written, voluntary, informed consent.

Exclusion Criteria

1. Previous treatment with any other investigational or not investigational agents within 28 days of first day of study drug dosing.
2. Other primary malignancy with \<5 years clinically assessed disease-free interval, except basal cell skin cancer, cervical carcinoma in situ, or other neoplasms judged to entail a low risk of relapse.
3. Grade III/IV cardiac problems as defined by the New York Heart Association Criteria (i.e., congestive heart failure, myocardial infarction within 6 months of study)
4. Severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes, chronic renal disease, or active uncontrolled infection).
5. Known brain metastasis.
6. Known chronic liver disease (i.e., chronic active hepatitis, and cirrhosis).
7. Known diagnosis of human immunodeficiency virus (HIV) infection.
8. Previous radiotherapy to \>=25 % of the bone marrow.
9. Major surgery within 2 weeks prior to study entry.
10. Expected non-compliance to medical regimens.

Eligible Sex

ALL

Accepts Healthy Volunteers

No